Compare Nucor Corporation (NUE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Nucor Corporation trades at $248 (market cap $55.91B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.3× Nucor Corporation's market cap, and Nucor Corporation pays a 0.91% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NUE | VRTX | |
|---|---|---|
Market Cap | $55.91B | $128.16B |
Volume | 1,062,743 | 806,603 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $557.96 |
52-Week Low | $131.78 | $407.37 |
Typical Hold Time | 78 Days | 120 Days |
Enterprise Value | $60.32B | $122.29B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 1.96% on the day, amid a neutral technical signal with mixed moving averages and oscillators. Recent earnings show Q1 and Q2 2026 beats, but Q3 guidance of $5.75 EPS is pending. Revenue for 2025 was $32.49B with a net income margin of 7.99%, while 2026 projections indicate a rebound to $36.1B revenue and 7.98% margin. The company maintains a strong balance sheet with $4.14B cash and a debt-to-asset ratio of 20.23% for 2025.
Outlook remains cautiously optimistic with a consensus price target of $266.88, implying ~8% upside, supported by 57.58% analyst buy ratings. Risks include competitive pressures from a new $15B Iowa steel mill and volatile steel prices, but Nucor's low-cost operations and dividend consistency (214th consecutive payout) provide stability. Investors should monitor Q3 earnings for confirmation of growth trajectory amid sector headwinds.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
